Brazil is currently the Latin American epicenter of the coronavirus disease 2019 (COVID-19) pandemic, whose impacts have permeated the economic, social, and healthcare spheres. Amid its worst health crisis, the country has also been struggling with antiscience political narratives that promote the widespread use of chloroquine, hydroxychloroquine, and, more recently, the antiparasitic ivermectin. As a result, an increased demand for these pharmaceuticals has been observed across the country, with a sales increase of >50% in comparison to 2019 (Conselho Federal de Farmácia 2020). This steep increase in the use of such drugs, however, may pose risks to Brazil's highly biodiverse biomes-an issue that overlaps with the country's precarious wastewater-treatment situation. Data from 2018 indicated that almost half of the Brazilian population does not have access to sewage collection; the northern and northeast regions (historically at economic disadvantage) are particularly vulnerable because only 10.49 and 28.01%, respectively, of their inhabitants have access to adequate sanitation (Figure 1). Nationwide, 46% of collected sewage is treated, but high treatment rates (>80%) are observed in only 21 of the 100 largest cities (Instituto Trata Brasil 2018). Such poor sanitation conditions have detrimental effects on human health and the environment. Many contemporary pollutants are pharmaceuticals, which is concerning because of their toxicity to aquatic organisms, ever increasing amounts, and relative chemical stability. Organ damage, reproductive toxicity, hormonal disruption, behavioral changes, mutagenicity, and carcinogenicity are some of the reported effects of widely used drugs on various amphibian, fish, and invertebrate species (Organisation for Economic